🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nashik
Clinical trial register · India

Clinical Trials in Nashik, 2026

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1132 matching records held by the registry are in this view. Synced 27 Sep 2026, 03:16 UTC
1132
Studies in scope
all four open statuses
613
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
Nashik 10 Mumbai 9 Bangalore 8 Kolkata 8 Pune 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca4 Tolmar Inc.2 Pfizer2 Hoffmann-La Roche1 Eli Lilly and Company1
Site location
Nashik10 Mumbai9 Bangalore8 Kolkata8 Pune7
All 45 locations
Target enrolment
to

Trials with a site in Nashik

10 of 1132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
DrugsPF-07248144·Exemestane·Everolimus·Fulvestrant
Pfizer
Phase 3
400
Surat, Bengaluru, Nashik, Pune
2025-08-05
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
DrugsPF-07220060·Ribociclib·Abemaciclib·Palbociclib
Pfizer
Phase 3
1,035
Surat, Gurugram, Bangalore, Mumbai, Nashik, Pune, Thane, New Delhi
2025-01-06
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
DrugsXeloda·Epirubicin·Datopotamab Deruxtecan·Olaparib
AstraZeneca
Phase 3
1,902
Bengaluru, Delhi, Kolkata, Marg Jaipur, Nagpur, Nashik, Thiruvananthapuram, Vadodara
2023-11-14
By invitation
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
NCT05645536Breast Cancer
DrugsTOL2506·Tamoxifen·Exemestane·Anastrozole
Tolmar Inc.
Phase 3
250
Surat, Bangalore, Bengaluru, Mysore, Nagpur, Nashik, Pune, Erode
2022-12-28
Active, closed
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512Breast Cancer
DrugsEribulin·Datopotamab Deruxtecan·Nab-paclitaxel·Capecitabine
AstraZeneca
Phase 3
644
Bangalore, Jaipur, Kolkata, Nagpur, Nashik, New Delhi, Puducherry, Vadodara
2022-05-16
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
DrugsPertuzumab·Trastuzumab deruxtecan·Doxorubicin·Trastuzumab
AstraZeneca
Phase 3
927
Gurgaon, Howrah, Nagpur, Nashik, New Delhi, Raipur, Rishikesh, Surat
2021-10-25
Active, closed
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866Breast Cancer
DrugsVinorelbine·Eribulin·Datopotamab Deruxtecan·Capecitabine
AstraZeneca
Phase 3
732
Gurgaon, Howrah, Hyderabad, Jaipur, Kolkata, Nashik, Surat, Visakhapatnam
2021-10-18
Active, closed
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT04906395Breast Cancer
DrugsTOL2506·Tamoxifen·Exemestane·Anastrozole
Tolmar Inc.
Phase 3
250
Vijayawada, Visakhapatnam, Ahmedabad, Surat, Bengaluru, Mysore, Nagpur, Nashik
2021-07-01
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04873362Breast Cancer
DrugsHerceptin·Trastuzumab emtansine·Tecentriq·Trastuzumab
Hoffmann-La Roche
Phase 3
1,188
Ahmedabad, Bangalore, Mumbai, Nashik, Pune, New Delhi, North WEST Delhi, Ratnagiri Kilminnal
2021-05-04
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
DrugAbemaciclib
Eli Lilly and Company
Phase 3
5,637
Hyderabad, Ahmedabad, Vadodara, Gurgaon, Bangalore, Trivandrum, Mumbai, Nashik
2017-07-12
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-india/city/nashik

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in India and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,132 studies in total at the last sync on 27 Sep 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies with a site in Nashik that also match the filters currently applied.

How many clinical trials are recruiting in Nashik?

1 of the 10 studies on this page are recruiting new participants as of the 27 Sep 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 8 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nashik), 10 studies
PhaseStudiesRecruitingShare
Phase 3101100%

Most active sponsors

Lead sponsors with the most studies (Nashik)
Lead sponsorStudiesRecruiting
AstraZeneca40
Pfizer21
Tolmar Inc.20
Eli Lilly and Company10
Hoffmann-La Roche10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.